mosaiques group – 
the worldwide leader in clinical proteomics!

Do you want to work with the gold standard in proteome analysis? 

Are you aiming to develop a new diagnostic tool or create a novel drug? Then proteome analysis is the right tool to support these efforts, as it deciphers information about protein alterations in your body.

Explore what we can accomplish together:

Develop high-quality diagnostics or new drugs with us!

Innovative diagnostics or drugs require valid, reproducible biomarkers, which can depict the complexity of the diseases at the proteome level.

This capability is enabled by mosaiques’ clinical proteome analysis, as demonstrated in numerous evidence-based studies.

Our technology for defining the proteome - the entirety of all proteins and peptides – has been proven to be valid, robust, and reproducible. It is based on over 20 years of expertise, demonstrated in more than 100 studies with over 400 publications in renowned scientific journals, in collaboration with 1,200 top researchers and physicians.

While some diseases, especially chronic diseases and various cancers, have already been defined, hundreds of thousands of questions remain to be explored. No single company can do this alone.

Therefore, mosaiques offers its unique proteome analysis technology as a service for researchers and clinicians.


clinical studies




years of research

Why is proteomics the key to modern medicine?

Diseases are generally not associated with changes in only one protein, but with multiple proteomic alterations. A quantitative and qualitative evaluation of the proteins is necessary for obtaining comprehensive and representative knowledge.

Diseases arise at the molecular level, at the level of proteins. At this level, the decisive biochemical processes that are responsible for disease development and control take place. This diagnostic level is generally not accessible with other ‘omics technologies and can only be accessed by proteomics. 

mosaiques group - the worldwide leader in clinical proteomics!

The mosaiques group has invented and developed clinical proteomics through the integration of capillary electrophoresis with mass spectrometry. The basis for the successful use of clinical proteome analysis was the generation of proprietary software tools for handling big data. 

The gained big data from all measurements are stored in the mosaiques Human Proteome Database.

Today, our technology can be successfully utilized for clinical diagnostics and biomarker identification.

What clinical proteomics is already capable of today?

Mosaiques has already developed biomarkers for numerous diseases through more than 100 clinical studies and over 400 publications. Several in-vitro diagnostic (IVD) tests have been derived from these findings, and they are already available on the market. 

The same applies in the context of the drug development process, where proteome analysis has led to the identification of relevant drug targets and drug candidates.

Given the knowledge available today about several diseases and their development, mosaiques can efficiently and precisely identify biomarkers in a targeted and timely manner.

Artificial intelligence -AI-

AI cannot provide us with insights in the absence of valid data. It can only provide further results if it is given access to fundamentally correct and reliable data. Irrelevant or incorrect data not focused on the biological pathophysiological disease processes, such as almost all diagnostic parameters currently in use, cannot provide advanced results.

It is correct that, when applied to and based on fundamental biological data, AI will epochally change and massively improve medicine in the next 10 years, based on objective scientific knowledge, if the data and knowledge on the proteome are being used!

mosaiques' proteome analysis technology is at the center and at the beginning of AI-based health solutions!

A few examples of successful application

  • Guiding Personalized Therapeutic Intervention: the detection of vulnerable populations at risk of unfavorable health outcomes (Keller et al.), prediction of future major kidney or cardiovascular events, and in silico prediction of drug responses to prevent unfavorable outcomes (Jaimes Campos et al.).
  • To determine if a chronic disease will progress to serious organ damage, we have generated in-vitro diagnostics for chronic kidney diseases, coronary artery disease, and heart failure.
  • To avoid unnecessary biopsies or endoscopic examinations, we have established diagnostics tests for the differential diagnosis of chronic kidney diseases, the early detection of cholangiocarcinoma, the clarification of prostate cancer following elevated prostate-specific antigen (PSA) values, and the detection of bladder cancer.
  • To demonstrate the effectiveness of new or repurposed drugs for other indications, we provide proteome analysis though collaboration or as a service, depending on the use of the proteome database.

Unique selling points

The proteome analysis by mosaiques

- chronic diseases, escape the scourge of humanity!

The molecular proteomics revolution

- the key to a long, healthy life

Proteome analysis

the "perpetuum mobile" of modern medicine and the acceptance by the supervisory authorities

Worldwide unique proteome database

Basis of international medical research / -perpetuum mobile-

Benefits of proteomic analysis

= only the proteome analysis recognizes the chonic diseases in time


© copy right 2022